USPTO has published Phosphagenics’ application for a Pharmaceutical Formulation patent which is intended to protect the use of TPM in a broad range of injectable formulations (Pub. No: 20190015329, Pub. Date: 17/01/19). This patent, along with a joint Phosphagenics-Terumo patent specifically for TPM/Propofol, was referred to by the company in a November 2017 update.
The TPM formulation is described as suitable for topical, enteral or parenteral administration, but is considered particularly suitable as an injectable formulation.
https://www.uspto.gov/
USPTO has published Phosphagenics’ application for a...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6 | 1.963K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 93002619 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 60312650 | 22 |
View Market Depth
| Last trade - 09.59am 23/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |